Prognosis: Misconception

A New Vaccine Frontrunner

As competitors publicly entered the race to produce a vaccine, drug giant Merck stayed quiet about its development plans. Now, the company has revealed it’s working on two vaccines and a treatment pill -- emerging as a frontrunner in the development contest. Although the company has refused to give firm timelines for its research, it has pledged to make its vaccines and pill available globally, if they're successful. Riley Griffin talked with Merck Chief Executive Kenneth C. Frazier about the company's plans.See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.

Reality TV stars are freezing their eggs on camera. Lawmakers in DC are debating federal protection for IVF. Hundreds of millions of dollars are being invested in slick startups that market fertility treatments for all. But this rapid growth has revealed cracks in the system. Misconception, a new series from Bloomberg’s Prognosis, follows reporter Kristen V. Brown on her own intimate journey as she uncovers the business of fertility. Along the way, she finds a fractured industry — a profit-driven field of medicine that thrives on dueling messages of hope and fear as people gamble everything for a chance at a baby.